Inflammasomes are multimeric protein complexes that promote inflammation (through specific cleavage and production of bioactive IL-1 and IL-18) and pyroptotic cell death. The central role of inflammasomes in combating infection and maintaining homeostasis has been studied extensively.
INTRODUCTION
Our immune system is comprised of germ-line encoded pathogen recognition receptors (PRR) that sense microbial invasion or tissue injury. PRR sensing of pathogen-associated molecular patterns (PAMP) or damage-associated molecular patterns (DAMP) initiate transcripAbbreviations: AIM2, absent in melanoma-2; ALR, absent in melanoma-2-like receptors; ASC, apoptosis-associated speck-like protein containing a CARD; ATG, autophagy-related; BHB, -hydroxybutyrate; BMDC, bone marrow-derived dendritic cells; BMDM, bone marrow-derived macrophages; BRCC3, BRCA1/BRCA2-containing complex subunit 3; Ca 2+ , calcium; CARD, caspase activation and recruitment domain; CLP, cecal ligation and puncture; COP, CARD-only proteins; DAMP, damage-associated molecular patterns; DC, dendritic cells; DRD1, dopamine receptor D1; DSS, dextran sodium sulfate; EP4, E-prostanoid 4; FADD, Fas-associated death domain protein; FBXL2, F-box and leucine-rich repeat protein 2; FliI, Flightless-I; FOXO3a, Forkhead box O 3a; FXR, Farnesoid X receptor; GSDMD, gasdermin D; HDAC6, histone deacetylase 6; IFI16, interferon gamma inducible protein 16; IRAK1, IL 1 receptor associated kinase 1; KCl, potassium chloride; LC3B, microtubule-associated protein light chain 3B; LRR, leucine-rich repeat; LRRFIP2, leucine-rich repeat Fli-I-interacting protein 2; MARCH7, membrane-associated RING finger protein 7; miR, micro RNA; MSU, monosodium urate; N-GSDMD, N-terminal fragment of GSDMD; NLR, Nod-like receptors; NLRC, Nod-like receptor family CARD domain containing protein; NLRP, Nod-like receptor family pyrin domain containing protein; NOD2, nucleotide-binding oligomerization domain containing protein 2; PAMP, pathogen-associated molecular patterns; PKA, protein kinase A; POP, pyrin-only proteins; K + , potassium; PRR, pathogen recognition receptor; PTPN22, protein tyrosine phosphatase, non-receptor Type 22; RIPK2, receptor interacting protein kinase 2; ROS, reactive oxygen species; SESN2, sestrin2; SIRT2, sirtuin2; TIM, transmembrane immunoglobulin and mucin domain; TRIM, tripartite motif; TTP, tristetraprolin; ULK1, Unc-51 like autophagy activating kinase 1; UTR, untranslated region; WT, wild-type tional programming to induce inflammation that includes production of cytokines and chemokines. However, inflammation is a double-edged sword that needs to be tightly controlled: although critical for the con- Upon sensing a danger signal, an inflammasome sensor recruits an adaptor molecule apoptosis-associated speck-like protein containing a caspase-recruitment domain (ASC), and a cysteine protease caspase-1, to form an inflammasome complex (Fig. 1) . 1, 2 This multimeric complex has recently been shown to consist of 10-12 NLR molecules. [3] [4] [5] Within this complex, caspase-1 undergoes autoproteolysis and becomes NLRP- 
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F I G U R E 1 Cytosolic sensors that assemble inflammasome complex and the consequence of inflammasome activation. Members of NLR family (NLRP1b, NLRP2, NLRP3, NLRP6, NLRP7, NLRP9b, NLRP12, NLRP14, NLRC4), HIN200 family (AIM2, IFI16), and Pyrin can assemble an inflammasome complex. Upon activation, these inflammasome sensors recruit adaptor ASC and caspase-1 to form the inflammasome complex. Inflammasome complex formation results in activation of caspase-1. Active caspase-1 cleaves pro-IL-1 and pro-IL-18 to release their bioactive forms to induce inflammation, and cleaves gasdermin D (GSDMD) to release N-terminal fragment of gasdermin D (N-GSDMD). N-GSDMD forms pores on the cell membrane to induce inflammatory cell death known as pyroptosis activated. Active caspase-1 has 2 major functions within the cellsfirst, it processes pro-IL-1 and pro-IL-18 into their bioactive forms to promote inflammation; second, it cleaves gasdermin D (GSDMD) to release N-terminal fragment of GSDMD (N-GSDMD), which promotes inflammatory cell death known as pyroptosis. [6] [7] [8] [9] Several cytosolic sensors have been described to form an inflammasome complex.
To date, the 5 well-characterized inflammasomes include NLRP1b, 1 NLRP3, [10] [11] [12] [13] 26 and IFI16. 27 In this review, we will focus on NLRP3 and discuss the recent literature that describes mechanisms to negatively regulate the NLRP3 inflammasome.
NLRP3 INFLAMMASOME
NLRP3 is one of the well-studied NLR that assembles an inflamma- and peritoneal macrophages. [34] [35] [36] Importance of the NLRP3 inflammasome is highlighted by a plethora of studies that show a central role for this sensor in eliminating pathogens and maintaining cellular homeostasis. 37 Conversely, aberrant activation of the NLRP3 inflammasome has been shown to cause metabolic disorders and autoinflammatory diseases such as gout, type II diabetes, cancer, familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease. 10, [37] [38] [39] [40] [41] [42] Here, we discuss mechanisms by which the NLRP3 inflammasomes are kept in check to limit excessive inflammation and disease.
NEGATIVE REGULATION OF NLRPINFLAMMASOME ACTIVATION
To understand how the NLRP3 inflammasome is negatively regulated, it is equally important to know what molecules/pathways are required for its activation. Activation of the NLRP3 inflammasome requires 2 signals-a priming signal through PRR that activates the NF B and MAPK signaling pathway to up-regulate Nlrp3 expression, and an activating signal that promotes NLRP3 oligomerization to assemble the inflammasome complex. 43 In this review, we will take a top-down approach and discuss how the NLRP3 inflammasome can be negatively regulated. The negative regulation of NF B signaling relating to the NLRP3 inflammasome has been recently reviewed elsewhere, 44 and thus, we will focus on direct negative regulation of Nlrp3 mRNA expression (posttranscriptional regulation) and NLRP3 protein levels (posttranslational regulation), and the NLRP3 inflammasome complex assembly.
Posttranscriptional regulation of NLRP3 mRNA
One of the major functions of a priming signal is to induce the expression of NLRP3 mRNA and accumulate NLRP3 protein for optimal activation of the inflammasome. Indeed, acute activation of BMDM and BMDC through TLR-2 agonist PAM3CSK4
or TLR-4 agonist LPS for up to 4 h dramatically increases both mRNA and protein levels of NLRP3. 45 However, chronic 51 Overexpression of miR-133b in HEK293T cells reduced the protein levels of NLRP3, whereas inhibition of miR-133b increased the protein levels of HEK293T cells in vitro. 51 Importantly, miR-133b inhibited NLRP3
inflammasome activation and ameliorated allergic inflammation in a mouse model of allergic rhinitis. 51 Luciferase reporter assay in 54 Thus, TTP directly binds and regulates NLRP3 mRNA expression to repress NLRP3 inflammasome activity. Interestingly, most of these negative regulators described in here do not regulate other inflammasomes ( Fig. 2A ).
Negative regulation of NLRP3 by posttranslational modifications
NLRP3 proteins are constitutively expressed in macrophages and DC.
Priming through TLR increases NLRP3 protein levels required for optimal NLRP3 inflammasome activation. Upon stimulation with a ligand, NLRP3 translocates to the mitochondria and oligomerizes; both necessary steps for eventual NLRP3 inflammasome activation. How can these necessary steps be regulated by modulating NLRP3 protein to inhibit the activation of the NLRP3 inflammasome? We will discuss recent reports on posttranslational modification of NLRP3, and inhibition of NLRP3 trafficking, as mechanisms to negatively regulate NLRP3 inflammasome activation (Fig. 2B ).
Posttranslational modifications to negatively regulate the NLRP3 inflammasome
Proteins are tightly regulated by posttranslational modifications such as phosphorylation, glycosation, ubiquitination, sumoylation, neddylation, s-nitrosylation, methylation, and acetylation. Several of these modifications are also involved in the negative regulation of the NLRP3 protein; these have been reviewed in detail by Yang et al. 55 recently.
Using N1-8 macrophage cell lines (stably expressing C-terminal FLAG tagged NLRP3), Juliana et al. 56 showed that NLRP3 proteins are heavily ubiquitinated in basal condition. Acute LPS priming for 10 min was sufficient to induce deubiquitination of NLRP3, a critical step for its activation. 56 The deubiquitination of NLRP3 following priming event is not specific to LPS/TLR4 because similar results were also observed during acute PAM3CSK4 (TLR-2 agonist), poly I:C (TLR-3 agonist), R837 (TLR-7 agonist), and CpG (TLR-9 agonist) stimulations of murine BMDM. 57, 58 Inhibition of this deubiquitination step by deubiquitinating enzyme inhibitors PR-619 or WP1130 during LPS+ATP stimulation of N1-8 macrophages completely abolished caspase-1 activation. 56 NLRP3 inflammasome activation in this acute TLR stimulation setting was independent of transcriptional events, but it required kinase activity of IL 1 receptor associated kinase 1 (IRAK1). 57, 58 A subsequent study identified deubiquitinating enzyme BRCA1/BRCA2-containing complex subunit 3 (BRCC3), which promoted NLRP3 deubiquitination to promote NLRP3 activation. 59 How kinase activity of IRAK1 fits in this puzzle is unknown and needs further investigation. It is possible that IRAK1-mediated phosphorylation is a prerequisite step for BRCC3 to promote NLRP3 deubiquitination. Regardless, these studies indirectly suggested that ubiquitination of NLRP3 negatively regulates its activation. Recent studies have uncovered possible ubiquitin ligases that negatively regulate NLRP3 activation. Yan et al. 60 showed that dopamine signals through the dopamine receptor D1 (DRD1) to inhibit monosodium urate (MSU), nigericin, ATP, and alum-induced NLRP3 inflammasome activation in LPS-primed murine BMDM. IL-1 and IL-18 cytokines produced during neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neuroinflammation, LPS-induced shock, and MSU-induced peritonitis were significantly increased in Drd1-deficient mice, suggesting a protective role for dopamine signaling in regulating NLRP3 inflammasome activation in vivo. 60 In LPS-primed murine BMDM, dopamine-DRD1 signaling induces cAMP expression; cAMP then binds NLRP3 and promotes K48-linked ubiquitination through the E3 ubiquitin ligase membrane-associated RING finger protein 7 (MARCH7). 60 Interestingly, the ubiquitinated NLRP3 is degraded in a phagosome rather than a proteasome. More detailed biochemical studies are needed to identify specific lysine residues on NLRP3 that are ubiquitinated by MARCH7. Another report identified that E3 ubiquitin ligase F-box L2 (FBXL2) ubiquitinates NLRP3 to negatively regulate its expression in an in vitro ubiquitination tube assay. 61 In vitro overexpression studies showed that FBXL2 directly interacts with NLRP3 but not with the W73A mutant of NLRP3. 61 Thus, Tryptophan-73 residue of NLRP3 is critical for FBXL2 and NLRP3 interaction. In vitro ubiquitination assay further showed that K689R mutant of NLRP3 was poly-ubiquitinated to a lesser extent compared with wild-type (WT) NLRP3 by FBXL2. 61 Thus, FBXL2 ubiquitinates NLRP3 on the Lysine-689 residue to promote proteasomal degradation. 61 Of note, FBXL2 and NLRP3 studies were done in an in vitro system and whether Fbxl2-deficiency induces aberrant NLRP3 inflammasome activation in vivo is not known. Tripartite motif protein (TRIM) family members have been shown to negatively modulate NLRP3 protein expression. TRIM20 promotes NLRP3 degradation through unc-51-like autophagy activating kinase 1 (ULK1), Beclin 1, and ATG16L1-mediated autophagy. 62 TRIM20 bound with both exogenously expressed and endogenous NLRP3, ULK1, Beclin1, and ATG16L1 in HEK293T cells. 62 Mechanistically, in IFN-stimulated cells, TRIM20 interacts with NLRP3 via its SPRY domain and further recruits ULK1, Beclin 1, and ATG16L1 to facilitate autophagic degradation of NLRP3. 62 TRIM31, a TRIM family protein with E3 ubiquitin ligase activity, negatively regulates ATP, nigericin, and alum-induced NLRP3 inflammasome activation in LPS-primed mouse peritoneal macrophages. 63 TRIM31 directly interacted with NLRP3 as demonstrated by in vitro binding assays (in vitro transcribed/translated TRIM31 and NLRP3 in a tube interacted with each other) and promoted Lys-48-linked polyubiquitination and proteasomal degradation of NLRP3 in HEK293T and mouse peritoneal macrophages. 63 As a result, compared with WT controls, Trim31-deficient mice were highly susceptible to alum-induced peritonitis and DSS-induced colitis, both NLRP3-dependent diseases. 63 These studies highlight the crucial role of E3 ubiquitin ligases in posttranslational regulation of NLRP3.
Several studies have reported phosphorylation of NLRP3 as a potential mechanism that negatively regulates inflammasome activation. NLRP3 dephosphorylation by protein tyrosine phosphatase, non-receptor Type 22 (PTPN22) was reported to be critical for activation of the NLRP3 inflammasomes and induction of DSS-induced colitis in mice, suggesting phosphorylation as the limiting step for NLRP3 inhibition. 64 Indeed, phosphorylated NLRP3 was shown to be sequestered in the autophagosomes in LPS + MSU-treated BMDC, and that the phosphorylated NLRP3 recovered from autophagsome enriched fractions were significantly increased in Ptpn22-deficient BMDC. 65 PTPN22 interacted with NLRP3 upon MDP, MSU, and ATPinduced NLRP3 inflammasome activation in LPS-primed THP1, MM6, BMDC and PBMC, and dephosphorylated Tyrosine-861 on NLRP3. 64 Although these studies did not elucidate the kinases that phosphorylate Tyrosine-861, it is clear that the kinase has to be a tyrosine kinase. 64 One of the likely candidates includes spleen tyrosine kinase, which has been implicated in the regulation of the NLRP3 inflammasome. 66 Another study, by Mortimer et al., demonstrated that PGE2 at nanomolar concentrations can effectively inhibit ATP, nigericin, MSU, and silica-induced NLRP3 inflammasome activation in LPS-primed BMDM. 67 Similarly, stimulation of PGE2 receptor Eprostanoid 4 (EP4) using EP4 agonist CAY10598 inhibited activation of the NLRP3 inflammasomes in LPS-primed BMDM. 67 Moreover, PGE2-mediated inhibition of LPS + nigericin-induced caspase-1 and IL-1 activation was not observed in BMDM with siRNA-mediated deletion of protein kinase A (PKA), suggesting PGE2-EP4 needs PKA to inhibit NLRP3 inflammasome. 67 In vitro PKA kinase assays demonstrated that PKA directly phosphorylates NLRP3 proteins purified from HEK293T cells at Ser-295 residue. 67 Phosphorylation of NLRP3 Ser-295 turns off NLRP3 ATPase activity and inhibits inflammasome assembly. 67 Mutation in the human NLRP3 corresponding to Ser-295 have been linked with autoinflammatory disorders, highlighting the importance of Ser-295 residue in negative regulation of NLRP3 inflammasomes. 67 Phosphorylation of NLRP3 Pyrin domain at Ser-5 residue has also been reported to inhibit inflammasome activation. 68 Immortalized Nlrp3-deficient macrophages reconstituted with WT NLRP3, but not S5E or S5D mutant, activated caspase-1 and produced IL-1 in response to LPS and nigericin. 68 Although the Serine kinase that phosphorylates the Ser-5 residue remains unknown, Phosphatase 2A (PP2A) was identified as the phosphatase that dephosphorylates Ser-5 to regulate NLRP3 activity. 68 Thus, immortalized macrophages with siRNAmediated knockdown of PP2A produced significantly reduced levels of IL-1 in response to LPS and nigericin. 68 Stutz et al. 68 proposed that NLRP3 is phosphorylated at Ser-5 in an unprimed state, which limits Pyrin-Pyrin homotypic interaction and NLRP3 oligomerization to inhibit inflammasome activation.
It is important to note that phosphorylation of NLRP3 is not always associated with negative regulation. Indeed, a recent study by Song et al. 69 has demonstrated NLRP3 phosphorylation as a critical priming step for inflammasome activation. The critical residue required for activation of NLRP3 inflammasome was identified to be in human NLRP3 and Ser-194 residue in mouse NLRP3. 69 Thus, LPS-primed BMDM from mouse harboring a S194A mutant version of NLRP3 protein (Nlrp3 S194A knock in mouse) failed to activate NLRP3 inflammasome in response to ATP, nigericin, MSU and poly I:C stimulations. 69 Not surprisingly, Nlrp3 S194A mice were highly resistant to 10 mg/kg LPS injections. 69 Several studies have demonstrated a role for nitric oxide in negatively regulating NLRP3 inflammasome activation. IFN-signaling inhibited nigericin-induced NLRP3 inflammasome activation in PAM3CSK4-primed murine peritoneal macrophages in a nitric oxide-dependent manner. 70 In support of a regulatory role for nitric oxide, treatment of LPS-primed peritoneal macrophages or THP1 macrophages with SNAP (a nitric oxide donor) attenuated NLRP3 inflammasome activation in response to ATP, nigericin, and MSU. 70, 71 Chronic LPS stimulation of peritoneal macrophages for 12 h induced nitric oxide, which inhibited NLRP3 inflammasome activation in response to nigericin in vitro. 70 Similarly, IFN-pretreatment of murine BMDM inhibited NLRP3 inflammasome activation during Mycobacterium tuberculosis infection which required nitric oxide. 72 Mechanistically, nitric oxide promotes S-nitrosylation of the NLRP3 protein, and this modification inhibits the ability of NLRP3 to assemble the inflammasome complex. 70, 72 S-nitrosylation of NLRP3 does not result in protein degradation or destabilization, as the NLRP3 protein remained stable during SNAP treatment of PAM3CSK4-primed peritoneal macrophages. 70 Follow-up studies are needed to identify the exact cysteine residues that are S-nitrosylated and the molecular mechanisms (e.g., physical interference, deactivation of NLRP3) by which S-nitrosylation of NLRP3 inhibits its function.
Regulation of processes that activate and assemble the NLRP3 inflammasome
Upon receiving the priming signal and optimal production of NLRP3, the inflammasome is ready to be assembled. As discussed earlier, several common proximal events have been proposed to activate and assemble the NLRP3 inflammasome. The 2 major mechanisms that are well-established in the literature include (1) K + efflux, and (2) mitochondrial damage-associated changes such as production of ROS and other host factors. As can be envisaged, mechanisms that restrict these activating cues can specifically inhibit the activation of NLRP3 inflammasome (Fig. 3A) .
Preventing K + efflux to inhibit the NLRP3 inflammasome
Petrillia et al. 73 first observed that the addition of potassium chloride (KCl) (130 mM concentration) to prevent K + efflux inhibited activation of the NLRP3 inflammasome in LPS-primed mouse peritoneal macrophages as well as in THP1 cells by various stimuli including ATP, nigericin, MSU, and Escherichia coli. Thus, lowering the concentrations of cytosolic K + was sufficient to activate the NLRP3 inflammasome. Interestingly, the low levels of K + induced NLRP3
inflammasome assembly in a cell-free system; that is, THP1 cell lysates prepared in 10 mM KCl spontaneously activated caspase-1. 73 Although these data suggest a direct role for K+ in promoting inflammasome assembly, further studies are needed to elucidate the precise molecular mechanisms. Given that K + efflux seems to be the common trigger for activation of NLRP3 inflammasome in response to both bacterial toxins and particulate matter, 28, 74 inhibiting K + efflux can negatively regulate NLRP3 inflammasome in various inflammatory conditions. The ketone metabolite -hydroxybutyrate (BHB), which is elevated during starvation, caloric restriction, high-intensity exercise, and low-carb ketogenic diet, 75, 76 specifically inhibits NLRP3 inflammasome in murine BMDM and CD14+ primary human monocytes. 77 Mechanistically, BHB prevents K + efflux to reduce NLRP3 inflammasome activation. 77 Although the precise molecular details of how BHB prevents K + efflux remain unknown, BHB-mediated NLRP3 inflammasome inhibition seems to be independent of starvation-associated mechanisms such as autophagy. 77 Mutation in LIPIN2, a member of the LIPIN family of proteins, triggers the NLRP3-associated inflammatory disorder called Majeed syndrome. 78 Primary human macrophages or murine BMDM with siRNA-mediated knockdown of LIPIN2 produced significantly elevated levels of IL-1 in response to LPS and ATP, a classical activator of the NLRP3 inflammasome. 79 When compared with control cells, siRNA knockdown of LIPIN2 in RAW264.7 macrophages significantly increased K + efflux following 2 mM ATP treatment. 79 Thus, LIPIN regulates K + efflux, a critical step for NLRP3 inflammasome activation. 28, 73, 74 Utilizing Lipin2-deficient mice, Lorden et al. 79 showed in peritoneal macrophages that LIPIN-2 negatively regulates ATP-induced opening of P2X7 receptor channel to inhibit K + efflux. Further investigation is needed to elucidate precise mechanisms associated with TIM-3-mediated inhibition of NLRP3 activity.
Clearance of damaged mitochondria to limit NLRP3 inflammasome activation
One of the central mechanisms that promote NLRP3 inflammasome activation is mitochondrial dysfunction. The downstream mechanisms by which mitochondrial damage promotes NLRP3 inflammasome activation has been reviewed previously. 18 inflammasome activation during LPS and palmitic acid stimulation in vitro. 83 Thus, FOXO3a promotes autophagy to negatively regulate the NLRP3 inflammasome. More recently, Hemin and its derivative cobalt, protoporphyrin, were reported to promote both autophagosome formation and autophagy flux. 84 As a result Hemin inhibited NLRP3 inflammasome activation in both human and murine macrophages in vitro, and during MSU-induced peritonitis in mice in vivo. 84 Similar to autophagy, several studies have reported a role for mitophagy in clearance of damaged mitochondria and regulation of NLRP3 inflammasome activity. Nucleotide-binding oligomerization domain containing 2 (NOD2) and receptor interacting protein kinase 2 (RIPK2) promote phosphorylation and activation of a mitophagyassociated molecule, ULK1, during influenza virus (mouse adapted 85 Thus, mice deficient in NOD2 and RIPK2 exhibit uncontrolled hyperactive inflammasome activation (as demonstrated by aberrant IL-18 production) and are susceptible to influenza virus infection when compared with controls. 85 Given that PR8-infection induces the production of NLRP3 inflammasome-associated IL-1 and IL-18 cytokines, 86, 87 Lupfer et al. 85 proposed that NOD2/RIPK2-signaling axis negatively regulates the NLRP3 inflammasome. Follow up studies by Lupfer et al. 88 showed that Citrobacter rodenitum infection of Nod2 and Ripk2-deficient BMDM induced increased NLRP3 inflammasome activation as demonstrated by caspase-1 cleavage and IL-18 production. Zhong et al. 89 further showed that NF B signaling (which is required for priming of NLRP3) negatively regulates excessive inflammation by promoting p62-dependent clearance of damaged mitochondria. As such, LPS-primed BMDM deficient in p62 have dramatic accumulation of damaged mitochondria following ATP, alum, and MSU stimulation (classical activators of the NLRP3 inflammasomes), which promote aberrant caspase-1 activation, IL-1 production, and cell death. 89 Thus, the NF B-p62-mitophagy pathway serves as a cell-intrinsic mechanism to restrict host response by negatively regulating excessive NLRP3 inflammasome activation. 89 sestrin2 (SESN2) facilitates mitophagy by promoting mitochondrial aggregation and K63-linked ubiquitination of damaged mitochondria, and by increasing the levels of ULK1 in murine BMDM during LPS + ATP stimulation. 90 Thus, Sesn2-deficient BMDM display increased caspase-1 activation during LPS + ATP-induced activation of the NLRP3 inflammasome. 90 As a result, Sesn2-deficient mice are highly susceptible to LPS shock as demonstrated by rapid death of 100% of the Sesn2-deficient mice by 48 h following 12 mg/kg intraperitoneal LPS injection. 90 Sesn2-deficient mice also produce increased levels of IL-1 and IL-18 during CLP-induced polymicrobial sepsis and significantly higher percentage of Sesn2-deficient mice succumb to CLP-induced septic death. 90 Taken together, these studies highlight the importance of autophagy and mitophagy in clearance of damaged mitochondria and regulation of the NLRP3 inflammasomes (Fig. 3A) .
Inhibition of NLRP3 trafficking to the mitochondria
Upon activation, NLRP3 needs to translocate to the mitochondria to assemble the inflammasome complex. 91 Thus, mechanisms that target the cytoskeleton molecules such as microtubule and actin can negatively regulate activation of the NLRP3 inflammasome (Fig. 3B) . negatively regulates NLRP3 inflammasome activation by restricting NLRP3 trafficking to the mitochondria. 93 Inhibition of SIRT2 activity by AGK2 (a SIRT2 inhibitor) in LPS-primed J774 macrophages increased IL-1 production after nigericin stimulation. 93 Acetylated -tubulin is required for Dynein-dependent localization of NLRP3 to the mitochondria. 93 SIRT2 actively deacetylates -tubulin to restrict NLRP3 trafficking to mitochondria and inhibit assembly of the inflammasome complex. 93 Actin polymerization regulates various cellular processes that include motility, cytokinesis, and vesicular trafficking. 94 Upon activation with ATP or nigericin, NLRP3 interacts with F-actin, which negatively regulates NLRP3 activity in PMA-primed THP1 cells. 94 F-actin-mediated interaction and inhibition of NLRP3 required
Flightless-I (Fli-I) and LRR Fli-I-interacting protein 2 (LRRFIP2). 94 Concurrently, production of IL-1 and caspase-1 activation were significantly increased in PMA-primed THP1 monocytes or LPS-primed murine peritoneal macrophages upon shRNA-mediated deletion of Fli-I or LRRFIP2. 94, 95 Biochemical studies showed that LRRFIP2
and Fli-I facilitates NLRP3's interaction with F-actin to inhibit NLRP3 inflammasome activity. 94, 95 Fli-I also sequesters caspase-1 and inhibits caspase-1 activation in this complex. 95 Importantly, siRNA-mediated (Fig. 3C ).
Histone deacetylase 6 (HDAC6) negatively regulate NLRP3 inflammasome activation by sequestering NLRP3. 96 Murine BMDM with shRNA-mediated knockdown of HDAC6 demonstrated higher levels of caspase-1 activation and IL-1 production following LPS + ATP and LPS + nigericin stimulation. 96 Interestingly, this negative regulation was independent of HDAC6's deacetylase activity as demonstrated by failure of Tubastatin A (TSA-a selective HDAC6 deacytlase activity inhibitor) to rescue the increased caspase-1 and IL-1 cleavage in HDAC6-silenced BMDM. 96 Given that the protein level of NLRP3 did not change following shRNA-mediated HDAC6 knockdown in BMDM, it was posited that HDAC6 sequesters NLRP3. 96 In support, NLRP3 coimmunoprecipitated with HDAC6 when expressed together in HEK293T cells. 96 Binder of Ubiquitin Zinc finger (Buz) domain of HDAC6 was required for HDAC6's interaction with NLRP3, suggesting HDAC6 interaction with ubiquitinated NLRP3 negatively regulates the inflammasome activity. 96 Given that NLRP3 is a cytosolic sensor, it is likely that the HDAC6 sequesters NLRP3 in the cytoplasm and not in the nucleus of the cell. However, recent studies have shown that NLRP3 is also present in the nucleus of T cells. 97 Thus, it is also possible that HDAC6 may sequester NLRP3 in the nucleus. Farnesoid X receptor (FXR), a master regulator of bile acid homeostasis, was shown to negatively regulate bile acid-induced NLRP3 inflammasome activation. 98 Bile acids such as deoxycholic acid and chenodeoxycholic acid activated caspase-1 and IL-1 in WT peritoneal macrophages, which were increased in Fxr-deficient peritoneal macrophages. 98 Although the precise molecular mechanisms remain to be explored, FXR coimmunoprecipitated with NLRP3 and caspase-1 in THP1 cells both in unstimulated and LPS-stimulated conditions, suggesting FXR-mediated sequestration of NLRP3 and caspase-1 as a possible mechanism for tempering NLRP3 inflammasome activation. 98 Cytochrome c sequesters NLRP3 in the cytosol to inhibit inflammasome activation. 99 inhibited LPS-induced release of IL-1 [109] . Of note, a recent study with THP1 cells expressing doxycycline inducible CARD18 did not find any role for CARD18 in inhibiting IL-1 secretion upon LPS + nigericin stimulation, although caspase-1 activation was slightly reduced in CARD18 expressing THP1 cells. 111 The precise mechanisms by which these COP inhibit caspase-1 activation remain to be elucidated, and why they interact with certain CARD proteins and not others (i.e., their specificity) are not completely understood.
CONCLUSIONS
NLRP3 is a central global inflammasome sensor that activates and assembles inflammasome complex in response to a wide array of stimuli. Given the promiscuous nature of NLRP3, the negative regulation of NLRP3 is critical to prevent unwanted inflammation and tissue damage. In this review, we focused on the cellular mechanisms that are In addition to the cell-intrinsic factors that inhibit activation of the NLRP3 inflammasome discussed in this review, several microbe-associated factors can also negatively regulate the NLRP3 inflammasome. 114 Despite the amount of papers published on NLRP3 activation, we still lack a complete understanding of negative regulatory pathways, and several important questions still remain unanswered. As discussed in this review, there are many layers of negative regulation to inhibit NLRP3 activation, yet aberrant activation of the NLRP3 inflammasome is commonly observed in various disease settings. Specifically, deficiency in just one negative regulatory pathway is enough to promote aberrant NLRP3 activation. What are the reasons for this failure to regulate aberrant NLRP3 activation?
Are these diverse mechanisms of NLRP3 regulation not redundant?
Are negative regulatory pathways specifically activated in response to specific stimuli? Importantly, most of these mechanistic studies are always performed and validated in macrophages and DC. Do the same rules of negative regulation also apply to other immune cells such as neutrophils, T cells, and B cells that play major roles in inflammatory disorders? Future efforts should be geared towards understanding the contribution of these negative regulators in translational settings.
Undoubtedly, a clear understanding of the basic biology and precise cellular and molecular mechanisms of negative regulation of NLRP3
will aid in the development of future therapeutics that can effectively treat NLRP3-associated inflammatory diseases.
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